Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viking Thera (NQ: VKTX )

51.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Thera

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Why Viking Therapeutics Stock Is Skyrocketing Today
The clinical-stage biopharmaceutical company should soon be closer to potentially launching its first product. 
Via The Motley Fool
CON Stock: 7 Things to Know as Concentra Group Starts Trading Today
Concentra Group stock is a hot topic on Thursday as investors prepare for CON stock to start trading with its IPO today. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
Viking Therapeutics Unveils Monthly Weight-Loss Shot, And Rocks Eli Lilly, Novo Nordisk
Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug. 
Via Investor's Business Daily
Goodbye Open Seating! Southwest Airlines Announces Major Policy Shift.
Southwest Airlines is making major changes to its boarding policy as the air travel company is getting rid of open seating next year. 
Via InvestorPlace
Viking Therapeutics (VKTX) Stock Pops on Plans to Start Late-Stage Weight Loss Drug Trials
Viking Therapeutics stock is up on Thursday as VKTX investors react to the company preparing for a Phase 3 trial of its weight loss drug. 
Via InvestorPlace
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $6,600 Today
Via Benzinga
Smart Money Is Betting Big In VKTX Options
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday morning and we have all of the latest news traders need to know about them! 
Via InvestorPlace
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks
It takes a special set of circumstances for high-growth stocks to double in value in one year but analyst says these three can do it. 
Via InvestorPlace
Nvidia, Ford, Chipotle, Viking Therapeutics, Tesla: Why These 5 Stocks Are On Investors' Radars Today
On Wednesday, major U.S. indices closed significantly lower. The Dow Jones Industrial Average fell 1.25% to 39,853.87. 
Via Benzinga
Topics Stocks
Exposures US Equities
VKTX Stock Earnings: Viking Therapeutics Beats EPS for Q2 2024
VKTX stock results show that Viking Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Viking Therapeutics Stock Climbs On Q2 EPS Beat
Viking Therapeutics shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the key figures from the report: 
Via Benzinga
Missed Out on Eli Lilly? These 2 Healthcare Stocks Have Big Catalysts on the Horizon.
Eli Lilly is still a smart pick, but these two stocks could grow more in the near term. 
Via The Motley Fool
3 Monster Stocks in the Making to Buy Right Now
They're small now, but these stocks could grow much larger. 
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
3 Undervalued Biotech Stocks With Breakout Potential
Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
Via InvestorPlace
Is Viking Therapeutics a Millionaire-Maker?
This biotech stock fits the profile of a potentially big winner to a T. 
Via The Motley Fool
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition
These biotech stocks have promising outlooks that will bring major fortune to investors. Buy before it is too late. 
Via InvestorPlace
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics?
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... 
Via Benzinga
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. 
Via Benzinga
Eli Lilly, Novo Nordisk Fall As Roche Releases Weight-Loss Drug Data
Roche released early-stage data on its oral weight-loss drug. 
Via Investor's Business Daily
Is Viking Therapeutics the Best Biotech Stock for You?
Let's look beyond the hype the company is generating this year. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
There’s always a strong case for undervalued biotech stocks especially with newer innovation and demand for better treatment. 
Via InvestorPlace
Is Viking Therapeutics Stock Running Out of Steam?
Viking's stock has tripled in less than a year, and its red-hot valuation could have investors thinking twice about buying it today. 
Via The Motley Fool
Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
Both competitors have promising lead programs, and enough cash, too. 
Via The Motley Fool
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been 
Via MarketBeat
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
This pharma company is posting double-digit revenue growth. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.